1. Catalog
  2. Focus on: Biomarkers, MRI and PSMA PET Imaging in ...
Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast (2026)
Availability
On-Demand
Expires on May 22, 2027
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credit Credits
1.5 Participation Credits

New for 2026, Focus on: are a series of accredited sessions offering an in-depth exploration of key clinical topics aligned with AUA’s ongoing needs assessments. This session provides a deeper dive for the urologic care team to examine how emerging biomarkers, advanced MRI techniques, and PSMA PET imaging are reshaping prostate cancer care.

ACKNOWLEDGEMENTS
Independent educational grant support provided by:
  • Blue Earth Diagnostics, Inc.
  • Lantheus Medical Imaging
After participating in this CME activity, participants will be able to:
  1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care.
  2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging.
  3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them.
  4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments.
  5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy).
FACULTY DISCLOSURES
Name Company Name Relationship Type End Date
Michael A. Carducci, MD Acrivon Consultant or Advisor Current
Astra Zeneca Consultant or Advisor Current
Amgen Consultant or Advisor Current
Mack Roach III, MD No relevant financial relationships to disclose
Simpa S. Salami, MD, MPH Bayer Pharma Scientific Study or Trial Current
Mohummad Minhaj Siddiqui, MD No relevant financial relationships to disclose

EDUCATION COUNCIL DISCLOSURES
Education Council 2025

COI REVIEW WORK GROUP DISCLOSURES
COI Review Work Group 2025

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2026
Expiration Date: May, 2027

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association